RecruitingPhase 4NCT05721170

Impact of Beta Blockers on TAVI (BETA-TAVI)

Impact of Beta-blockers Among Patients Undergoing TAVI: a Randomized Multicenter Trial

Sponsor

National and Kapodistrian University of Athens

Enrollment

347 participants

Start Date

Jun 1, 2024

Study Type

INTERVENTIONAL

Conditions

Aortic Valve Stenosis

Summary

This is a prospective, multicentre, investigator-initiated, randomized clinical trial clinical trial investigating the impact of beta-blockers administration among patients undergoing TAVI for severe aortic valve stenosis. Adults already receiving beta-blockers be assigned randomly in 1:1 ratio to either continue or withdraw the beta-blockers medication at least 72 hours before and at least 7 days after TAVI. The primary endpoint is permanent pacemaker implantation rates in 7 days after the procedure. Secondary endpoints include death, cardiogenic shock and arrhythmias/conduction abmormalities with time frame 12 months.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Beta blocker for people with aortic valve stenosis. The study is currently recruiting participants at 2 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.